Form 4: Alnylam Director Peter Kellogg Acquires Stock Options

Director Peter Kellogg acquired stock options in Alnylam Pharmaceuticals, Inc. on May 16, 2024.

Summary

• Peter Kellogg, a director of Alnylam Pharmaceuticals, acquired 5,228 stock options on May 16, 2024.
• The exercise price of these options is $151.22.
• The options vest upon the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the anniversary.
• The options expire on May 16, 2034.
• Following the transaction, Kellogg directly owns 5,228 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of stock options by a director could be seen as a slightly positive signal, but it's a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance.

Industry Context

This is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are often part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages to align the interests of management with those of shareholders.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates